Male hormone-interfering drugs and meningioma development

Laura Giraldi, Jørgen Vinsløv Hansen, Jan Wohlfahrt, Mads Melbye, Kåre Fugleholm, Tina Nørgaard Munch

Research output: Contribution to journalJournal articleResearchpeer-review

6 Citations (Scopus)
64 Downloads (Pure)

Abstract

Background
Extremely strong associations between male hormone-interfering drugs and meningiomas have been reported in two previous studies, but these findings are limited by small size of the study populations and possibly by surveillance- and selection bias. Thus, such possible and indeed very interesting association must be investigated in a large, unselected cohort. Accordingly, the aim of this study was to determine whether patients exposed to male hormone-interfering drugs had a higher risk of meningioma development in a nationwide cohort study.

Methods
A retrospective Danish nationwide cohort study with follow-up from January 1, 1996 to December 31, 2016. Exposure was use of male hormone-interfering drugs (5-α-reductase-inhibitors, luteinizing hormone-releasing hormone agonist, steroidal antiandrogen, and nonsteroidal antiandrogen). Hazard ratio of first-time diagnosis of meningioma according to drug use was estimated using Cox proportional hazards model with adjustment for age and birth year.

Results
The cohort included 244,696 men of which 64,047 had used male hormone-interfering drugs. Overall 444 meningiomas occurred during follow-up. No significant association was observed between use of male hormone-interfering drugs and the occurrence of meningioma (hazard ratio 1.02, 95% confidence interval 0.82–1.27). Similar results were observed 0–1, 2–4, and 5+ years after first use. In explorative analyses, no elevated risk association was observed for specific drugs (5-α-reductase-inhibitors, luteinizing hormone-releasing hormone agonist, steroidal antiandrogen, and nonsteroidal antiandrogen).

Conclusion
As opposed to previous studies, we found no evidence of an increased risk of meningioma in men treated with male hormone-interfering drugs.
Original languageEnglish
Article numbervdz046
JournalNeuro-Oncology Advances
Volume1
Issue number1
Number of pages6
DOIs
Publication statusPublished - 2019

Cite this